Small Animal Clinical Pharmacology - CYF MEDICAL DISTRIBUTION

More documents

Recommendations

Info

INDEX Nitrous oxide 89, 94–95 Nizatidine 478, 479 NK 1 receptor antagonists 474–475 NMDA receptors 114 antagonism 94–95, 96 Noise phobia 135, 145 Non-cellular mechanisms of drug action 4 Nonadrenergic and noncholinergic (NANC) transmitters 61 Nondepolarizing muscle relaxants 67, 75–77 adverse effects 76–77 clinical applications 75–76 drug interactions 77 formulations and dose rates 76 mechanism of action 76 pharmacokinetics 76 Nonopioid antitussives 464 Nonproprietary (common or generic) name 8 Nonreceptor binding sites 31 Nonsteroidal antiinflammatory drugs see NSAIDs Nonsystemic antacids 482–483 Noradrenaline see Norepinephrine (noradrenaline) Noradrenergic transmission 71, 72 Norepinephrine (noradrenaline) 61, 62, 69, 70, 72 and behavior 128 sedative action 114 Norfloxacin 181–183 Nortriptyline 136–138 Nosocomial infections 149 NSAIDs 287–308 adverse effects 45, 294–297 approved for small animal practice 297–303 clinical applications 287–288 known drug interactions 297 in liver disease 52 mechanism of action 288–293 metabolism in cats vs dogs 47 ocular therapy 558, 562–563 pharmacokinetics and pharmacodynamics 293–294 prostaglandins and inflammation 288–289 in renal disease 52 unapproved agents for small animal practice 303–306 Nuclear receptors 9 Nucleic acid synthesis inhibiting antibacterials 178–185 Nucleic acids 9 Nystatin 555 O Obesity, influence on pharmacokinetics 18–19 N-Octyl bicycloheptene dicarboximide (MGK 264) 232 Ocular therapy 557–573 achieving adequate tissue concentrations 557–559 anti-inflammatory 558, 559–564 antibacterial 558, 564–566, 567 antifungal 567–568 antiviral 568–569 corneal dehydrating agents 572 drug characteristics 559 dry eye 570, 572–573 glaucoma 558, 570–571 lesion location and routes of administration 557 lubricants 573 miotics 558, 569–570 mydriatics 558, 569 parasites 257–258 special considerations 557–559 topical anesthetics 558, 572 Off-label (extra-label) uses 26, 45, 68 Ofloxacin 564 Ointments 554, 564 Omeprazole 9, 481–482 adverse effects 51, 482 Ondansetron 475 Online journals 11 Opioid agonists 133, 318–326 partial 326–328 Opioid analgesics 310–329 Opioid antagonists 133, 319, 328–329 Opioid antitussives 464–465 Opioid GIT motility-modifying drugs 487–488 Opioid receptors 8, 63 adverse effects in relation to 313 agonist and antagonist activities 318 classes 310–311, 313 drug interactions 311–313 effector mechanisms 311 Opioids adverse effects 314–315 chemical structure 310 clinical applications 310 dosages and duration of action 318–319 importance of pre-emptive analgesia 309–310 indications and techniques 315–318 pharmacodynamics 318 pharmacokinetics 313–314 and sedatives, ‘neuroleptanesthesia’ 113 Oral administration 29–30 Oral antibacterials 152 Oral calcium preparations 507 Oral cephalosporins 167 Oral glycerin 571 Oral hypoglycemic agents 55, 512–515 Orbifloxacin 181–183 Organophosphates 9, 68, 232–234 adverse effects 49, 233 drug interactions 234 pharmacokinetics 232–233 toxicity 233–234 treatment of toxicity 233 Ormetoprim 156, 178, 239 Osteo-arthritis 297 Osteomyelitis, antibacterial drug choice 153 Otitis externa, topical medications 153, 554–556 Otitis media/interna, antibacterial drug choice 153 Ototoxicity 556 Ovulation induction 529, 530, 532 Oxacillin 162 Oxantel 203, 207, 209 Oxatomide 266, 267 Oxazepam 134–136, 135, 491 Oxibendazole 205, 206, 207 Oximes 233–234 Oxymorphone 319, 323 Oxytocin 532–533 P P-glycoprotein (P-gp) 54 Paclitaxel 336, 339–340 Pain animals presenting in 315 importance of pre-emptive analgesia 309–310 recognition and management 309 Pancreatic enzyme activity 15 Pancreatic enzyme replacements 516 Pancreatic function disorders 509–516 Pancreatic insufficiency 515–516 Pancreatic parasites 249 Pancuronium bromide 75–77 Paracetamol (acetaminophen) 305–306 adverse effects 47, 48, 51, 305–306 clinical applications 305 CNS action 293 toxicity 306 Paraffin 486 Parasites 245–260 Parasympathetic nervous system 59–60, 61–69 Parasympatholytics 75–78 Parasympathomimetics (cholinergic agonists) 74–75 Parathyroid disease 503–508 Parathyroid hormone (PTH) replacement 508 Paregoric 487–488 Parenteral antibacterials 152–154 Parenteral calcium preparations 507 Parenteral cephalosporins 167 Paromomycin 239 Paroxetine 138–140 Partial agonists 6 opioid 326–328 Partial coefficients, solubility of inhalational anesthesia 85–86 Particle size and drug absorption 13 Parturition induction 533, 538 Pathology and pharmacokinetics 18, 36–37, 50–52 Penicillamine 493 Penicillin G 161 Penicillin V 161 Penicillin-induced hypersensitivity 55 Penicillins 151, 155, 159–161 classes 161–163 Pentamidine isetionate 234, 237, 243, 250, 251 585
INDEX Pentazocine 319, 327 Pentobarbital 96 Pentosan polysulfate 307–308 Pentoxifylline 278–279 Peptide antibiotics 169–170 Peptide immunotherapy for autoimmune/allergic disease 285 Periodontitis, antibacterial drug choice 153 Peripheral muscle relaxants 67 Peripheral nerve blocks 110 Peripheral nervous system (PNS) 59 Permethrin 221, 222, 235–236 adverse drug reactions (ADRs) 45, 48, 236 toxicology 236 Pethidine (meperidine) 319, 322 Pharmaceutical drug interactions 54 Pharmacodynamics between-species differences 18 definition 3 drug interactions 54 Pharmacogenetic differences 19, 53–54 Pharmacokinetics 27–40 between-species differences 18 definition 2–3 and disease 18, 36–37, 50–52 dose calculations 38–40 drug interactions 54 physiological basis 27–33 and prescribing issues 33–37 and therapeutic drug monitoring (TDM) 37 within-species differences 18–19 <strong>Pharmacology</strong>, definition 1 Pharmacovigilance (postmarketing surveillance) 22, 44–46 Phenethicillin 161 Phenobarbital (phenobarbitone) 368–371 adverse effects 51, 132, 370 behavior modification 132 clinical applications 368 drug interactions 194–195, 370–371 formulations and dose rates 368, 369 mechanism of action 368–369 pharmacokinetics 269–270 Phenobarbitone see Phenobarbital Phenothiazines adverse effects 115–116, 471 antiemetic action 471–472 behavior modification 130–131 clinical applications 114–115 contraindications and precautions 116 derivatives 266 drug interactions 116, 471–472, 535 formulations and dose rates 115, 471 and ketamine combinations 105 mechanism of action 115, 471 pharmacokinetics 115, 471 sedative action 114–116 Phenoxybenzamine 71, 73–74, 81–82 586 Phenoxymethyl-penicillin (penicillin V) 161 Phentolamine 71, 73–74, 81–82 Phenyl pyrazoles 228–230 Phenylbutazone 302 Phenylephrine 569 Phenylpropanolamine 79–80, 143 adverse effects 80 clinical applications 79–80, 543 contraindications and precautions 80 drug interactions 80 Phenytoin 9 adverse effects 376, 429 antiarrhythmic action 429 anticonvulsant action 375–376 clinical applications 375 drug interactions 376, 429 formulations and dose rates 375, 427, 429 mechanism of action 375, 429 pharmacokinetics 375–376, 429 Pheromones 144–145 Phospholine iodide 570 Physical effects of non-cellular mechanisms of drug action 4 Physical state, influence on pharmacokinetics 18–19 Physicochemical cellular mechanisms of drug action 4 Physicochemical non-cellular mechanisms of drug action 4 Physicochemical properties, food–drug interaction 16 Physiological effects 13 Pilocarpine 570 extra-label uses 68 Pimobendan 385, 398–400, 403 Pindolol 133 Pinocytosis (receptor-mediated endocytosis) 29 Piperacillin 163 Piperazine 53, 203, 206, 219 derivatives 266 Piperonyl butoxide (PBO) 202, 232 Piroxicam 287, 306 Placebo effects 19–20 Plasma membrane enzymes 7–8 Plasma membrane-bound protein kinases, stimulation of 8 Platinum analogs 354–358 Plicamycin cancer chemotherapy 336, 352–353 in hypercalcemia 506 PMSG (eCH) 531, 532 Pneumocandins 196 Poiseuille–Hagan formulation 458 Polyene antibacterials, ocular therapy 567 Polyethylene glycol 3350 (PEG) 486 Polymorphous state 12 Polymyxin B, ocular therapy 566 Polymyxins 56, 151, 170 Polypeptide hormones 529–535 Polysulfated glycosaminoglycans (PSGAGs) 306–307, 308 Ponazuril 239 Posaconazole 193 Positive inotropic drugs 382, 395–397 Positive lusitropic agents (ventricular relaxation) 382, 400, 422–423 Postganglionic synapses 69, 70 Postmarketing surveillance (pharmacovigilance) 22, 44–46 Potassium-sparing diuretics 394–395 Povidone-iodine 552–553 ocular therapy 567 see also Iodine Praziquantel 203, 206, 207, 216–217 Prazosin 74, 403, 407–408 Prednisolone 263, 525, 527 and aurothiomalate 276 and ciclosporin 272 Prednisolone acetate, ocular therapy 558, 560 Pregnancy adverse drug reaction (ADRs) 50 and antibacterials 152 influence on pharmacokinetics 18–19 see also Abortion Preoperative analgesia 315–316 Prerenal azotemia 389 Prescribing instructions 26 pharmacokinetics 33–37 principles 23–26 Prilocaine 111 Primaquine phosphate 237, 243–244 Primidone 371–372 Procainamide 37, 53, 385, 427, 431–432 Procarbazine 346–347 Prochlorperazine 114–116 Progesterone 535–537 Progesterone receptor 9 Progestins 535–537 behavior modification 142–143 Prokinetic gastrointestinal drugs 483–485 Prolactin 533, 534, 535 Promazine 114–116 Promethazine 114–116 Propanolol 71, 419, 427, 435–436 adverse effects 50, 51, 133, 436 behavior modification 132–133 clinical applications 435 drug interactions 436 formulations and dose rates 436 mechanism of action 435–436 pharmacokinetics 436 special considerations 436 Propantheline 475–476 Propantheline bromide 68 Proparacaine 572 Propentofylline 146–147 Propofol 99–101 Proprietary names 10 Propylamine derivatives 266 Propylene glycol 56 Propylthiouracil 9, 48 Prostacyclin analogs 424 Prostaglandin agonists 571 Prostaglandin inhibition 294–295
Page 1 and 2:
An imprint of Elsevier Limited © E
Page 3 and 4:
CONTRIBUTORS Matthias J Kleinz Depa
Page 5 and 6:
Dedication To Tom, Rosalind and Jim
Page 7 and 8:
CHAPTER 1 PRINCIPLES OF CLINICAL PH
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
CHAPTER 2 CLINICAL PHARMACOKINETICS
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
CHAPTER 3 ADVERSE DRUG REACTIONS Un
Page 49 and 50:
CHAPTER 3 ADVERSE DRUG REACTIONS to
Page 51 and 52:
CHAPTER 3 ADVERSE DRUG REACTIONS
Page 53 and 54:
CHAPTER 3 ADVERSE DRUG REACTIONS He
Page 55 and 56:
CHAPTER 3 ADVERSE DRUG REACTIONS an
Page 57 and 58:
CHAPTER 3 ADVERSE DRUG REACTIONS wh
Page 59 and 60:
CHAPTER 3 ADVERSE DRUG REACTIONS at
Page 61 and 62:
CHAPTER 3 ADVERSE DRUG REACTIONS Ps
Page 63 and 64:
CHAPTER 3 ADVERSE DRUG REACTIONS su
Page 65 and 66:
CHAPTER 4 THE PHARMACOLOGY OF THE A
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
CHAPTER 5 ANESTHETIC AGENTS However
Page 91 and 92:
CHAPTER 5 ANESTHETIC AGENTS The gre
Page 93 and 94:
CHAPTER 5 ANESTHETIC AGENTS Table 5
Page 95 and 96:
CHAPTER 5 ANESTHETIC AGENTS doses.
Page 97 and 98:
CHAPTER 5 ANESTHETIC AGENTS ● hig
Page 99 and 100:
CHAPTER 5 ANESTHETIC AGENTS concent
Page 101 and 102:
CHAPTER 5 ANESTHETIC AGENTS X R 3 C
Page 103 and 104:
CHAPTER 5 ANESTHETIC AGENTS Emergen
Page 105 and 106:
CHAPTER 5 ANESTHETIC AGENTS inhalat
Page 107 and 108:
CHAPTER 5 ANESTHETIC AGENTS and enh
Page 109 and 110:
CHAPTER 5 ANESTHETIC AGENTS ● Exc
Page 111 and 112:
CHAPTER 5 ANESTHETIC AGENTS Pharmac
Page 113 and 114:
CHAPTER 5 ANESTHETIC AGENTS Central
Page 115 and 116:
CHAPTER 5 ANESTHETIC AGENTS Table 5
Page 117 and 118:
CHAPTER 5 ANESTHETIC AGENTS FURTHER
Page 119 and 120:
CHAPTER 6 SEDATIVES ● noradrenali
Page 121 and 122:
CHAPTER 6 SEDATIVES treatment, with
Page 123 and 124:
CHAPTER 6 SEDATIVES Benzodiazepines
Page 125 and 126:
CHAPTER 6 SEDATIVES It is not misci
Page 127 and 128:
CHAPTER 6 SEDATIVES respectively. H
Page 129 and 130:
CHAPTER 6 SEDATIVES Table 6.1 Sugge
Page 131 and 132:
7 Behavior-modifying drugs Kersti S
Page 133 and 134:
CHAPTER 7 BEHAVIOR-MODIFYING DRUGS
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
8 Antibacterial drugs Jill E Maddis
Page 155 and 156:
CHAPTER 8 ANTIBACTERIAL DRUGS phary
Page 157 and 158:
CHAPTER 8 ANTIBACTERIAL DRUGS dose
Page 159 and 160:
CHAPTER 8 ANTIBACTERIAL DRUGS Table
Page 161 and 162:
Page 163 and 164:
CHAPTER 8 ANTIBACTERIAL DRUGS Bacte
Page 165 and 166:
CHAPTER 8 ANTIBACTERIAL DRUGS lacta
Page 167 and 168:
CHAPTER 8 ANTIBACTERIAL DRUGS Antis
Page 169 and 170:
CHAPTER 8 ANTIBACTERIAL DRUGS intri
Page 171 and 172:
Page 173 and 174:
CHAPTER 8 ANTIBACTERIAL DRUGS inter
Page 175 and 176:
CHAPTER 8 ANTIBACTERIAL DRUGS Teico
Page 177 and 178:
CHAPTER 8 ANTIBACTERIAL DRUGS less
Page 179 and 180:
CHAPTER 8 ANTIBACTERIAL DRUGS Diffe
Page 181 and 182:
CHAPTER 8 ANTIBACTERIAL DRUGS forms
Page 183 and 184:
CHAPTER 8 ANTIBACTERIAL DRUGS ● I
Page 185 and 186:
CHAPTER 8 ANTIBACTERIAL DRUGS In an
Page 187 and 188:
CHAPTER 8 ANTIBACTERIAL DRUGS ● R
Page 189 and 190:
CHAPTER 8 ANTIBACTERIAL DRUGS RIFAM
Page 191 and 192:
9 Systemic antifungal therapy Josep
Page 193 and 194:
CHAPTER 9 SYSTEMIC ANTIFUNGAL THERA
Page 195 and 196:
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
10 Antiparasitic drugs Stephen W Pa
Page 205 and 206:
CHAPTER 10 ANTIPARASITIC DRUGS ●
Page 207 and 208:
CHAPTER 10 ANTIPARASITIC DRUGS Tabl
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Page 215 and 216:
CHAPTER 10 ANTIPARASITIC DRUGS leva
Page 217 and 218:
CHAPTER 10 ANTIPARASITIC DRUGS ●
Page 219 and 220:
CHAPTER 10 ANTIPARASITIC DRUGS Adve
Page 221 and 222:
CHAPTER 10 ANTIPARASITIC DRUGS Mech
Page 223 and 224:
CHAPTER 10 ANTIPARASITIC DRUGS Form
Page 225 and 226:
CHAPTER 10 ANTIPARASITIC DRUGS Mech
Page 227 and 228:
Page 229 and 230:
CHAPTER 10 ANTIPARASITIC DRUGS prod
Page 231 and 232:
CHAPTER 10 ANTIPARASITIC DRUGS Lufe
Page 233 and 234:
CHAPTER 10 ANTIPARASITIC DRUGS Adve
Page 235 and 236:
CHAPTER 10 ANTIPARASITIC DRUGS 62.5
Page 237 and 238:
CHAPTER 10 ANTIPARASITIC DRUGS incr
Page 239 and 240:
CHAPTER 10 ANTIPARASITIC DRUGS rest
Page 241 and 242:
CHAPTER 10 ANTIPARASITIC DRUGS The
Page 243 and 244:
CHAPTER 10 ANTIPARASITIC DRUGS 238
Page 245 and 246:
Page 247 and 248:
CHAPTER 10 ANTIPARASITIC DRUGS In a
Page 249 and 250:
CHAPTER 10 ANTIPARASITIC DRUGS func
Page 251 and 252:
CHAPTER 10 ANTIPARASITIC DRUGS Para
Page 253 and 254:
Page 255 and 256:
Page 257 and 258:
Page 259 and 260:
Page 261 and 262:
Page 263 and 264:
Page 265 and 266:
Page 267 and 268:
CHAPTER 11 GLUCOCORTICOSTEROIDS AND
Page 269 and 270:
Page 271 and 272:
Page 273 and 274:
Page 275 and 276:
12 Immunomodulatory therapy Michael
Page 277 and 278:
CHAPTER 12 IMMUNOMODULATORY THERAPY
Page 279 and 280:
Page 281 and 282:
Page 283 and 284:
Page 285 and 286:
Page 287 and 288:
Page 289 and 290:
Page 291 and 292:
Page 293 and 294:
CHAPTER 13 NONSTEROIDAL ANTI-INFLAM
Page 295 and 296:
Page 297 and 298:
Page 299 and 300:
Page 301 and 302:
Page 303 and 304:
Page 305 and 306:
Page 307 and 308:
Page 309 and 310:
Page 311 and 312:
Page 313 and 314:
Page 315 and 316:
CHAPTER 14 OPIOID ANALGESICS inflam
Page 317 and 318:
A Agonist opioid (morphine) B Parti
Page 319 and 320:
CHAPTER 14 OPIOID ANALGESICS admini
Page 321 and 322:
CHAPTER 14 OPIOID ANALGESICS may ac
Page 323 and 324:
CHAPTER 14 OPIOID ANALGESICS Small
Page 325 and 326:
CHAPTER 14 OPIOID ANALGESICS Clinic
Page 327 and 328:
CHAPTER 14 OPIOID ANALGESICS Contra
Page 329 and 330:
CHAPTER 14 OPIOID ANALGESICS respon
Page 331 and 332:
CHAPTER 14 OPIOID ANALGESICS Advers
Page 333 and 334:
CHAPTER 14 OPIOID ANALGESICS Advers
Page 335 and 336:
15 Cancer chemotherapy Jane M Dobso
Page 337 and 338:
CHAPTER 15 CANCER CHEMOTHERAPY to m
Page 339 and 340:
CHAPTER 15 CANCER CHEMOTHERAPY curr
Page 341 and 342:
CHAPTER 15 CANCER CHEMOTHERAPY Tabl
Page 343 and 344:
CHAPTER 15 CANCER CHEMOTHERAPY Clin
Page 345 and 346:
CHAPTER 15 CANCER CHEMOTHERAPY sion
Page 347 and 348:
CHAPTER 15 CANCER CHEMOTHERAPY In t
Page 349 and 350:
CHAPTER 15 CANCER CHEMOTHERAPY afte
Page 351 and 352:
CHAPTER 15 CANCER CHEMOTHERAPY Phar
Page 353 and 354:
CHAPTER 15 CANCER CHEMOTHERAPY Form
Page 355 and 356:
CHAPTER 15 CANCER CHEMOTHERAPY conc
Page 357 and 358:
CHAPTER 15 CANCER CHEMOTHERAPY ●
Page 359 and 360:
CHAPTER 15 CANCER CHEMOTHERAPY Phar
Page 361 and 362:
CHAPTER 15 CANCER CHEMOTHERAPY in t
Page 363 and 364:
CHAPTER 15 CANCER CHEMOTHERAPY Adve
Page 365 and 366:
CHAPTER 15 CANCER CHEMOTHERAPY best
Page 367 and 368:
CHAPTER 15 CANCER CHEMOTHERAPY Form
Page 369 and 370:
CHAPTER 15 CANCER CHEMOTHERAPY baso
Page 371 and 372:
CHAPTER 15 CANCER CHEMOTHERAPY D-MA
Page 373 and 374:
CHAPTER 16 ANTICONVULSANT DRUGS sei
Page 375 and 376:
CHAPTER 16 ANTICONVULSANT DRUGS bit
Page 377 and 378:
CHAPTER 16 ANTICONVULSANT DRUGS Kno
Page 379 and 380:
CHAPTER 16 ANTICONVULSANT DRUGS Mec
Page 381 and 382:
CHAPTER 16 ANTICONVULSANT DRUGS rap
Page 383 and 384:
CHAPTER 16 ANTICONVULSANT DRUGS exc
Page 385 and 386:
17 Drugs used in the management of
Page 387 and 388:
CHAPTER 17 DRUGS USED IN THE MANAGE
Page 389 and 390:
Page 391 and 392:
Page 393 and 394:
Page 395 and 396:
Page 397 and 398:
Page 399 and 400:
Page 401 and 402:
Page 403 and 404:
Page 405 and 406:
Page 407 and 408:
Page 409 and 410:
Page 411 and 412:
Page 413 and 414:
Page 415 and 416:
Page 417 and 418:
Page 419 and 420:
Page 421 and 422:
Page 423 and 424:
Page 425 and 426:
Page 427 and 428:
Page 429 and 430:
Page 431 and 432:
Page 433 and 434:
Page 435 and 436:
Page 437 and 438:
Page 439 and 440:
Page 441 and 442:
Page 443 and 444:
Page 445 and 446:
Page 447 and 448:
Page 449 and 450:
Page 451 and 452:
Page 453 and 454:
Page 455 and 456:
Page 457 and 458:
Page 459 and 460:
Page 461 and 462:
Page 463 and 464:
Page 465 and 466:
Page 467 and 468:
Page 469 and 470:
Page 471 and 472:
Page 473 and 474:
Page 475 and 476:
CHAPTER 19 GASTROINTESTINAL DRUGS C
Page 477 and 478:
CHAPTER 19 GASTROINTESTINAL DRUGS r
Page 479 and 480:
CHAPTER 19 GASTROINTESTINAL DRUGS
Page 481 and 482:
CHAPTER 19 GASTROINTESTINAL DRUGS c
Page 483 and 484:
CHAPTER 19 GASTROINTESTINAL DRUGS w
Page 485 and 486:
Page 487 and 488:
CHAPTER 19 GASTROINTESTINAL DRUGS F
Page 489 and 490:
CHAPTER 19 GASTROINTESTINAL DRUGS i
Page 491 and 492:
CHAPTER 19 GASTROINTESTINAL DRUGS L
Page 493 and 494:
CHAPTER 19 GASTROINTESTINAL DRUGS P
Page 495 and 496:
CHAPTER 19 GASTROINTESTINAL DRUGS F
Page 497 and 498:
Page 499 and 500:
CHAPTER 19 GASTROINTESTINAL DRUGS Z
Page 501 and 502:
CHAPTER 19 GASTROINTESTINAL DRUGS
Page 503 and 504:
Page 505 and 506:
Page 507 and 508:
Page 509 and 510:
Page 511 and 512:
Page 513 and 514:
Page 515 and 516:
CHAPTER 21 DRUGS USED IN THE TREATM
Page 517 and 518:
Page 519 and 520:
Page 521 and 522:
Page 523 and 524:
Page 525 and 526:
Page 527 and 528:
Page 529 and 530:
Page 531 and 532:
Page 533 and 534:
23 Drugs and reproduction Philip G
Page 535 and 536:
CHAPTER 23 DRUGS AND REPRODUCTION I
Page 537 and 538:
CHAPTER 23 DRUGS AND REPRODUCTION F
Page 539 and 540: CHAPTER 23 DRUGS AND REPRODUCTION C
Page 541 and 542: CHAPTER 23 DRUGS AND REPRODUCTION M
Page 543 and 544: CHAPTER 23 DRUGS AND REPRODUCTION F
Page 545 and 546: CHAPTER 23 DRUGS AND REPRODUCTION n
Page 547 and 548: CHAPTER 23 DRUGS AND REPRODUCTION E
Page 549 and 550: CHAPTER 23 DRUGS AND REPRODUCTION F
Page 551 and 552: 24 Topical dermatological therapy R
Page 553 and 554: CHAPTER 24 TOPICAL DERMATOLOGICAL T
Page 563 and 564: CHAPTER 25 OCULAR CLINICAL PHARMACO
Page 579 and 580: Index A α-adrenergic receptors 70,
Page 581 and 582: INDEX Antiplatelet drugs 456-457 pi
Page 583 and 584: INDEX Ceftazidime 168 Ceftiofur 166
Page 585 and 586: INDEX Drug receptors 4-8 Drug-drug
Page 587 and 588: INDEX Hepatic excretion 33 Hepatic
Page 589: INDEX Metabolism dogs vs cats 47 an
Page 593 and 594: INDEX Semicarbazone 230 Septic arth
show all

Small Animal Clinical Pharmacology - CYF MEDICAL DISTRIBUTION

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?